https://www.selleckchem.com/pr....oducts/2-3-cgamp.htm
ne possible explanation is antigenic overlap between normal renal tubular cells and tumor cells.Tumor mutational burden (TM, defined as the number of somatic mutations per megabase of interrogated genomic sequence, varies across malignancies. Panel sequencing-based estimates of TMB have largely replaced whole-exome sequencing-derived TMB in the clinic. Retrospective evidence suggests that TMB can predict the efficacy of immune checkpoint inhibitors, and data from KEYNOTE-158 led to the recent FDA approval of pembrolizumab for the TM
Like
Comment
Share
